Sunflower Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") is pleased to announce that it has been selected for the fourth batch of national traditional Chinese medicine procurement alliance. The Company will actively expand its influence in the medical field and enhance its
002737SZSE
Announcement on the Selection of Products for the Fourth Batch of National Traditional Chinese Medicine Procurement Alliance
✨ AI Summary
Sunflower Pharmaceutical Group Co., Ltd. has been selected for the fourth batch of national traditional Chinese medicine procurement alliance. The company aims to increase its OTC revenue share to 80% by 2025, leveraging its "14th Five-Year Plan" to enhance brand, products, and sales networks. This selection is expected to expand the company's influence and market share in the medical field. Investors are cautioned about potential market uncertainties and investment risks.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.